Owen Mumford

Activities: Manufacturing Drug Delivery

Our core values are based around three strong pillars that define who we are; heritage, safety and sustainability. We have been inventing life-enhancing devices for nearly 70 years that are tested and proven to deliver an industry benchmark in accuracy, ease and safety. Our purpose now is in working towards the future as we help to define what healthcare will look like going forward - bringing concepts and solutions to life in an accountable and sustainable way

Trending Articles

  1. Wacker Biotech to manufacture protein ingredients for MinervaX's late-stage GBS vaccine The vaccine is currently being prepared for Phase III trials, and aims to protect mothers and their babies from group B streptococcus infections
  2. Novartis' Kisqali plus ET bags FDA approval for HR+/HER2- breast cancer The decision comes off the back of the Phase III NATALEE clinical trial, which diminished the risk of disease recurrence by 25.1%
  3. AstraZeneca opens a 'people hub' at its Macclesfield site The energy-efficient building will offer AZ employees a collaborative space
  4. Ensuring cGMP compliance in cell and gene therapy manufacturing 3P discusses how companies can scale up their CGT manufacturing protocols while remaining compliant with stringent global regulations
  5. Piramal Pharma's sustainability goals get SBTi-validated The company wants to reduce its scope 1 and 2 GHG emissions by 42% by 2030, and is also working on developing a carbon reduction plan

Upcoming event

Boston Biotech Week

23-26 September, 2024 | Convention and exhibition | Boston, US See all

Related Content

Manufacturing

Owen Mumford’s near-term and net-zero targets approved by the SBTi

The company's long and short-term initiatives include the reduction of scope 1, 2 and 3 emissions by 42% by 2030, as well as reaching net-zero in greenhouse gas emissions
Drug Delivery

Expanding capacity through collaboration

Michael Earl, Director of Pharmaceutical Services at Owen Mumford, and Steven Kaufman, Vice President for Drug Delivery Systems, Stevanato Group, talk to Dr Kevin Robinson about their new partnership
Manufacturing

Owen Mumford refurbishment project completed by Efaflex

An Efaflex case study
Drug Delivery

Owen Mumford appoints new Director of Research and Development

Owen Mumford, a global leader in the design, manufacture and advancement of medical devices, has appointed Bal Johal as Director of Research and Development, effective 4 July 2022
Research & Development

Owen Mumford and Stevanato Group sign an exclusive agreement

Aidaptus disposable auto-injector platform, designed by Owen Mumford, will be offered to biopharma companies to support their drug development programmes, with engineering and manufacturing support provided by Stevanato Group
Regulatory

Owen Mumford announces on market release of UniSafe 1mL safety device for pre-filled syringes featuring industry-first spring-less mechanism

UniSafe platform uses unique spring-free mechanism to prevent accidental activation and drug leakage
Drug Delivery

Aidaptus - The next generation platform disposable auto-injector

Aidaptus gives audible and visual notifications for complete clarity during the injection procedure
Subscribe now